Blog
RSS FeedPosted by Michael Wonder on 13 May 2019
The UK’s new medicines pricing deal – opportunities and risks for pharma
10 May 2019 - January 2019 saw the introduction of the new Voluntary Scheme for Branded Medicines Pricing and Access ...
Posted by Michael Wonder on 13 May 2019
MPs call for 'life-changing' Kuvan to be made affordable
11 May 2019 - A number of MPs are calling on a drug company to make a "life-changing" treatment affordable ...
Posted by Michael Wonder on 09 May 2019
Lower price for MS drug paves the way for positive recommendation from NICE
9 May 2019 - A new, lower price for a drug to treat a rarer form of multiple sclerosis in adults ...
Posted by Michael Wonder on 09 May 2019
Hope for multiple sclerosis sufferers after green light for drug which can delay wheelchair use by seven years
9 May 2019 - Multiple sclerosis patients have welcomed an NHS decision to fund a “landmark” drug which can delay ...
Posted by Michael Wonder on 03 May 2019
NICE recommends Roche’s Tecentriq for metastatic NSCLC
3 May 2019 - NICE has published final draft guidance recommending Roche’s Tecentriq in combination with other therapies for metastatic ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 01 May 2019
NHS England finalises procurement to eliminate hepatitis C
1 May 2019 - After lengthy negotiations and a court battle, NHS England has reached agreement with three drug companies ...
Posted by Michael Wonder on 29 Apr 2019
NICE launches online resource to help development and adoption of new health technologies
29 April 2019 - HealthTech Connect, a new online resource provided by NICE to help identify and support new health technologies ...
Posted by Michael Wonder on 21 Apr 2019
NICE publishes final recommendation for Almirall's Ilumetri (tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis
17 April 2019 - Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is ...
Posted by Michael Wonder on 20 Apr 2019
Expanding the scope of costs and benefits for economic evaluations in health: some words of caution
18 April 2019 - Discussions regarding the appropriate scope of costs and benefits for inclusion in economic evaluation in healthcare have ...
Posted by Michael Wonder on 20 Apr 2019
NICE final guidance published for Cimzia
18 April 2019 - NICE has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol). ...
Posted by Michael Wonder on 16 Apr 2019
Akcea steals march on Alnylam with NICE approval
16 April 2019 - Advantage to Tegsedi over Onpattro. ...
Posted by Michael Wonder on 15 Apr 2019
No-deal risk recedes, but new Brexit delay adds to uncertainty
12 April 2019 - Delay means industry must sustain no-deal investment. ...
Posted by Michael Wonder on 14 Apr 2019
Cystic Fibrosis scandal: MP demands answers on delay of vital NHS drugs deal
11 April 2019 - Theresa May yesterday vowed to take action over the lack of an NHS deal for cystic fibrosis ...
Posted by Michael Wonder on 10 Apr 2019
Novartis’ Kisqali hit with NICE rejection
10 April 2019 - NICE has issued a draft guidance which does not recommend Novartis’ Kisqali (ribociclib), which is typically ...